首頁/ 健康/ 正文

2021 ASH 重磅 | Late-Breaking Abstracts彙總

一年一度的美國血液學會(ASH)年會是全球血液學領域規模最大、涵蓋最全面的國際學術盛會之一。今年,第63屆ASH年會將於12月11日~14日線上下及線上召開,目前,萬眾矚目的重磅研究Late-Breaking Abstracts(LBA)已經公佈,讓我們一起盤點一下吧。

01

摘要號:LBA-1

講題:

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma。

報告人:

Hervé Tilly

單位:

Department of Hematology and U1245, Centre Henri Becquerel and University of Rouen, Rouen, France

報告時間:

Tuesday, December 14, 2021, 9:00 AM-10:30 AM

02

摘要號:LBA-2

講題:

The Longitudinal Dynamics and Natural History of Clonal Hematopoiesis。

報告人:

Margarete A Fabre

單位:

University of Cambridge, Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom

報告時間:

Tuesday, December 14, 2021, 9:00 AM-10:30 AM

03

摘要號:LBA-3

講題:

Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B)。

報告人:

Alok Srivastava

單位:

Department of Hematology, Christian Medical College, Vellore, India

報告時間:

Tuesday, December 14, 2021, 9:00 AM-10:30 AM

04

摘要號:LBA-4

講題:

Integrated Genomic Analysis Identifies UBTF Tandem Duplications As a Subtype-Defining Lesion in Pediatric Acute Myeloid Leukemia。

報告人:

Masayuki Umeda

單位:

Department of Pathology, St。 Jude Children‘s Research Hospital, Memphis, TN

報告時間:

Tuesday, December 14, 2021, 9:00 AM-10:30 AM

05

摘要號:LBA-5

講題:

Efficacy of rFVIIFc for First-Time Immune Tolerance Induction (ITI) Therapy: Final Results from the Global, Prospective VerITI-8 Study。

報告人:

Lynn Malec

單位:

Versiti Blood Research Institute, Milwaukee, WI

報告時間:

Tuesday, December 14, 2021, 9:00 AM-10:30 AM

06

摘要號:LBA-6

講題:

Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study。

報告人:

Michael R。 Bishop

單位:

The David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL

報告時間:

Tuesday, December 14, 2021, 9:00 AM-10:30 AM

相關文章

頂部